Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
Blue curve MMWR spacer

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: Type 508 Accommodation and the title of the report in the subject line of e-mail.

Notice to Readers: Availability of Additional Trivalent Inactivated Influenza Vaccine for Adults (Afluria®)

On September 28, 2007, CSL Biotherapies, Inc., (King of Prussia, Pennsylvania) received approval from the Food and Drug Administration for use of Afluria®, a trivalent inactivated influenza vaccine (TIV) administered intramuscularly in persons aged >18 years (1). Afluria can be used for any adult influenza vaccine indication (2).

The addition of Afluria brings to six (five TIVs and one live, attenuated influenza vaccine) the number of seasonal influenza vaccines licensed for the U.S. market. CDC estimates that manufacturers of the six vaccines will supply a record 132 million doses of influenza vaccine for the 2007--08 influenza season.

Afluria is available in a 0.5 mL preservative-free, single-dose, prefilled syringe and in a 5 mL multidose vial containing 10 doses. Thimerosal, a mercury derivative, is added as a preservative to the multidose vial; each 0.5 mL dose contains 24.5 µg of mercury. Additional information is available from the manufacturer's package insert (3) and CSL Biotherapies, Inc., telephone 888-435-8633.


  1. Food and Drug Administration. Additional influenza vaccine approved for upcoming influenza season: approval increases available doses to record level. Rockville, MD: Food and Drug Administration; 2007. Available at
  2. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 2007;56(No. RR-6).
  3. Afluria [package insert]. King of Prussia, PA: CSL Biotherapies, Inc.; 2007. Available at

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to

Date last reviewed: 11/20/2007


Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A


Department of Health
and Human Services